Dexcom (DXCM) Shares Outstanding (2010 - 2026)

Dexcom (DXCM) has 17 years of Shares Outstanding data on file, last reported at $385.9 million in Q1 2026.

• Shares Outstanding for Q1 2026 came in at $385.9 million, down 1.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $385.9 million (down 1.58% YoY), and the FY2025 annual result was $384.8 million, down 1.51% from the prior year.
• Shares Outstanding held at $385.9 million in Q1 2026 per DXCM's latest filing, from $384.8 million in the prior quarter.
• Over five years, Shares Outstanding peaked at $400.7 million in Q2 2024 and troughed at $98.1 million in Q1 2022.
• A 5-year average of $372.5 million and a median of $387.6 million in 2023 frame the typical range for Shares Outstanding.
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding plunged 74.64% in 2022, then jumped 295.11% in 2023.
• A 5-year view of Shares Outstanding shows it stood at $386.3 million in 2022, then decreased by 0.23% to $385.4 million in 2023, then gained by 1.38% to $390.7 million in 2024, then fell by 1.51% to $384.8 million in 2025, then gained by 0.29% to $385.9 million in 2026.
• Business Quant data shows DXCM's Shares Outstanding at $385.9 million in Q1 2026, $384.8 million in Q4 2025, and $390.0 million in Q3 2025.